Literature DB >> 12798307

A recombinant vector expressing transgenes for four T-cell costimulatory molecules (OX40L, B7-1, ICAM-1, LFA-3) induces sustained CD4+ and CD8+ T-cell activation, protection from apoptosis, and enhanced cytokine production.

Douglas W Grosenbach1, Jeffrey Schlom, Linda Gritz, Alicia Gómez Yafal, James W Hodge.   

Abstract

The role of OX40L on the activation of T cells was investigated using poxvirus vectors expressing OX40L alone or in combination with three other T-cell costimulatory molecules: B7-1, ICAM-1, and LFA-3. Poxvirus vector-infected cells were used to stimulate nai;ve or activated CD4(+) and CD8(+) T cells. These studies demonstrate that (a) OX40L plays a role in sustaining the long-term proliferation of CD8(+) T cells in addition to the known effect on CD4(+) T cells following activation, (b) OX40L enhances the production of Th1 cytokines (IL-2, IFN-gamma, and TNF-alpha) from both CD4(+) and CD8(+) while no change in IL-4 expression was observed, and (c) the anti-apoptotic effect of OX40L on T cells is likely the result of sustained expression of anti-apoptotic genes while genes involved in apoptosis are inhibited. In addition, these are the first studies to demonstrate that the combined use of a vector driving the expression of OX40L with three other costimulatory molecules (B7-1, ICAM-1, and LFA-3) both enhances initial activation and then further potentiates sustained activation of nai;ve and effector T cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12798307     DOI: 10.1016/s0008-8749(03)00080-7

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

Review 1.  Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines.

Authors:  Lena Serghides; Mariana Vidric; Tania H Watts
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 2.  Enhancing poxvirus vectors vaccine immunogenicity.

Authors:  Juan García-Arriaza; Mariano Esteban
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Investigation on correlation between expression of CD58 molecule and severity of hepatitis B.

Authors:  Li Sheng; Jie Li; Bao-Tai Qi; Yu-Qiang Ji; Zhao-Jun Meng; Ming Xie
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

4.  Vaccines with enhanced costimulation maintain high avidity memory CTL.

Authors:  Sixun Yang; James W Hodge; Douglas W Grosenbach; Jeffrey Schlom
Journal:  J Immunol       Date:  2005-09-15       Impact factor: 5.422

5.  Anti-gastric cancer active immunity induced by FasL/B7-1 gene-modified tumor cells.

Authors:  Shi-Ying Zheng; De-Chun Li; Zhi-De Zhang; Jun Zhao; Jin-Feng Ge
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

Review 6.  Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.

Authors:  Shahram Salek-Ardakani; Michael Croft
Journal:  J Interferon Cytokine Res       Date:  2010-04       Impact factor: 2.607

7.  The detection of sLFA-3 in plasma of patients with hemorrhagic fever with renal syndrome.

Authors:  Ming Xie; Ping Chen; Lin-Jing He; Bao-Tai Qi; Ping Wang; Xiao-Fang Wang; Hui-Xun Ren
Journal:  Clin Exp Med       Date:  2008-09-27       Impact factor: 3.984

Review 8.  OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses.

Authors:  John Goulding; Vikas Tahiliani; Shahram Salek-Ardakani
Journal:  Immunol Rev       Date:  2011-11       Impact factor: 12.988

9.  Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer.

Authors:  Anthony S Malamas; Scott A Hammond; Jeffrey Schlom; James W Hodge
Journal:  Oncotarget       Date:  2017-08-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.